Royalty Pharma Plc Cl A RPRX

$68.97 -1.04 (-1.49%)

Valuation

Market cap
40,255,820,000
Revenue TTM
$2,378,190,000
Net income TTM
$770,950,000
P/E (trailing)
13.13
P/E (forward)
12.96
Profit margin
32.42%
Debt to equity
0.88

Trading

Volume
3,784,500
Avg volume
3,354,414
Day's range
$68.75 – $70.37
Shares out
575,001,000
Stochastic %K
75%
Beta
0.37
Analysts
Strong Buy
Price target
$71.57

Price

Company profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has...

Show more

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
212 883 0200
Website
https://www.royaltypharma.com
Address
110 East 59th Street, New York, United States

Latest news

Stocktwits

shitzushimazu Nov 11, 7:00 PM
$RPRX this has been such a nice performer in the last year! This will be a dividend aristocrat that you can set and forget for rest of your life!
0 replies
Stocktwits52wHighs Nov 11, 5:46 PM
$RPRX printed a new 52-week high today
0 replies
Laurentium Nov 9, 4:06 AM
$RPRX yes!
0 replies
fda_tracker Nov 5, 4:12 PM
$RPRX New PDUFA Date 2027-05-27 Royalty Pharma plc Link: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000026/rprx-20260930rpplcpressxre.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 replies
EarningsInsider Nov 4, 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-11-4-royalty-pharma-plc-stock/ $RPRX Royalty Pharma Earnings Transcript
0 replies
StocktwitsEarnings Nov 4, 12:44 PM
$RPRX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.26 down -61.19% YoY • Reported revenue of $690M up 13.25% YoY • Royalty Pharma raised full year 2026 Portfolio Receipts guidance to $3.5B to $3.55B, including expected Royalty Receipts growth of 10% to 11%, excluding future transactions.
0 replies
Merlintrader Nov 4, 9:07 AM
$RPRX reports Q3 earnings today before the open. Consensus: EPS $1.18 (vs $1.17 a year ago), revenue $885M. Call 8:00 AM ET: https://www.royaltypharma.com/investors/events/ Explore the chart, tested levels and technical scenarios on JustCharts: https://justcharts.merlintrader.com/#RPRX
0 replies
Night_Owl_Biotech Oct 29, 8:07 PM
$SNDX Attached are 2 screenshots from $RPRX 's investor presentation from 8/2026 and 9/2025 related to their investment in Incyte's/SNDX's Niktimvo. You will see in September 2025, RPRX noted Niktimvo's consensus 5-year sales target was 98% higher compared to its 5-year estimate at the time of funding. In August 2026, the increase in 5-year sales was only 22% higher compared to the time of funding. These are RPRX's estimates (not our estimates). If you believe Niktimvo's valuation is some multiple of projected sales, and Niktimvo's 5-year sales forecast is 38% lower today than it was in 9/2025 (198 v 122), then obviously Niktimvo's valuation is also roughly 38% lower than it was in 9/2025 (13 months ago). Investors shouldn't be alarmed. SNDX's CEO is really smart. Why exit via M&A when he gets generous stock grants every year no matter SNDX's share price Does anyone read RPRX's estimates differently? $INCY reported cash of $3.85B as of 9/30/26. SNDX's market cap is ~$1.3B
2 replies